Warhound values itself at $1.2 billion after securing $200 million to engineer military canines

The United States currently relies heavily on foreign sources for its military working dogs, a dependency that a new biotechnology firm intends to rectify through genetic engineering. On Thursday, Warhound emerged from stealth mode following the closure of a $200 million funding round, a move that places the company’s valuation at $1.2 billion.

Three primary factors drive the venture’s immediate operational strategy and market positioning. First, the company aims to address a critical supply chain gap; according to its launch materials, more than 80% of U.S. military working dogs are imported from Europe, and fewer than half of those imports are deemed fit for service. Second, Warhound seeks to mitigate health risks associated with traditional breeding. Co-founder Ben Lamm noted that many dogs fail training due to inherited conditions such as poor vision, hip dysplasia, or muscle atrophy. By editing genes derived from top-performing breeds like the Belgian Malinois and German Shepherd, the team intends to create a new type of dog optimized for longevity, speed, and olfactory precision.

Third, the firm will integrate hardware and software from Anduril Industries to enhance situational awareness. While the genetic modifications will occur within the animal, Anduril’s equipment—such as protective vests with data sensors and goggles—will operate on top of the dog. This technology is designed to transmit real-time information to human handlers, thereby improving coordination and safety during dangerous missions such as bomb detection and search operations.

The venture represents a collaboration between Colossal Biosciences, which provides the underlying gene-editing technology, and Palmer Luckey, the founder of Anduril. Lamm explained that the two met approximately a year ago at a conference, where Luckey advocated for greater support for military working dogs. Luckey serves as a partner in the venture but holds no equity, whereas Colossal retains ownership and supports the initiative by licensing its technology. Investors in the round include Sequoia, 8VC, Corner Ventures, and In-Q-Tel, the latter being a venture firm backed by U.S. intelligence agencies.

In terms of timeline, the first batch of dogs is scheduled to be cloned and incubated shortly, with births expected in early 2027. The company anticipates that these animals could begin service within two years. Viagen, another entity owned by Colossal, will handle the cloning process, leveraging a technology that boasts a high success rate and is currently used in Colossal’s endangered species programs. Although pricing has not yet been established, the target market includes the Department of Defense, various military service groups, police forces, and other first responders.

To address concerns regarding animal welfare and public safety, Warhound is working under the guidance of the American Humane Society to certify its training program. Lamm stated that each dog will undergo standard military working dog training and will be managed by the purchasing agency. The American Humane Society welcomed the partnership, noting that they look forward to ensuring the animals are treated humanely. The company also hopes that retired dogs will enter the Society’s Military Working Dog Reunification Program, which facilitates adoption for former service animals. Lamm indicated that the company has already briefed numerous government groups on its operations.